Effects of ALE-36 on gastric secretion, and gastric and duodenal ulcers induced in rats.
We examined the antisecretory and anti-ulcer effects of ALE-36 in rats. ALE-36 (3-30 mg/kg) dose-dependently inhibited gastric acid secretion in pylorus-ligated rats. However, the agent apparently increased the volume of gastric juice, and the Na+ and Cl- ion outputs. These changes were almost completely prevented by pretreatment with indomethacin, suggesting that endogenous prostaglandins in the gastric mucosa mediated the changes. Pretreatment with ALE-36 (3-30 mg/kg) inhibited the development of stress-, aspirin-, and indomethacin-induced gastric lesions, and mepirizole-induced duodenal ulcers. Repeated administration of ALE-36 significantly accelerated the healing of gastric ulcers induced by thermocautery.
Kyoi
T
T
Research Laboratories, Nippon Shinyaku Co. Ltd., Kyoto, Japan.
Yamamoto
O
O
Ide
Y
Y
Ueda
F
F
Kimura
K
K
D000818:Animals; D001562:Benzimidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D002712:Chlorides / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D004381:Duodenal Ulcer / Q000517:prevention & control*; D005750:Gastric Juice / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012964:Sodium / Q000037:antagonists & inhibitors; D013276:Stomach Ulcer / Q000517:prevention & control*
D001562:Benzimidazoles; D002712:Chlorides; C061955:methyl 2-(3,4-dimethoxystyryl)benzimidazole-4-carboxylate; D012964:Sodium; D007213:Indomethacin